Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial

Neurofibromatosis Type 1 (NF1) plexiform neurofibromas (PN) are progressive, multicellular neoplasms that cause morbidity and predispose to sarcoma. Treatment of Nf1(flox/flox);PostnCre mice with cabozantinib, an inhibitor of multiple tyrosine kinases, caused a reduction in PN size and number and di...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Fisher, Michael J., Shih, Chie-Schin, Rhodes, Steven D., Armstrong, Amy E., Wolters, Pamela L., Dombi, Eva, Zhang, Chi, Angus, Steven P., Johnson, Gary L., Packer, Roger J., Allen, Jeffrey C., Ullrich, Nicole J., Goldman, Stewart, Gutmann, David H., Plotkin, Scott R., Rosser, Tena, Robertson, Kent A., Widemann, Brigitte C., Smith, Abbi E., Bessler, Waylan K., He, Yongzheng, Park, Su-Jung, Mund, Julie A., Jiang, Li, Bijangi-Vishehsaraei, Khadijeh, Robinson, Coretta Thomas, Cutter, Gary R., Korf, Bruce R., Blakeley, Jaishri O., Clapp, D. Wade
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8275010/
https://ncbi.nlm.nih.gov/pubmed/33442015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-020-01193-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados